News | March 10, 2026
Hopewell Therapeutics sublicenses breakthrough LNP technology to Foxcroft for cancer vaccine development
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
This study evaluated a difficult-to-treat Crohn's disease patient population
The company has shown remarkable growth, posting a three-year CAGR of around 75% with an ARR of roughly Rs 100 crore and impressive gross margins
The facility is expected to become operational by FY2028-29
The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
The enhancements will improve environmental sustainability, strengthen material governance, and boost utility reliability
The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons
Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories
ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis
Subscribe To Our Newsletter & Stay Updated
